Pages that link to "Q34332019"
Jump to navigation
Jump to search
The following pages link to Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib (Q34332019):
Displaying 50 items.
- Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice (Q24288997) (← links)
- Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy (Q24814325) (← links)
- Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies (Q26751959) (← links)
- Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity (Q26771331) (← links)
- Modulatory effects of bortezomib on host immune cell functions (Q26795618) (← links)
- Regulatory myeloid cells in transplantation (Q26999875) (← links)
- Positive and negative regulation by NK cells in cancer (Q27004658) (← links)
- Current and emerging strategies for the prevention of graft-versus-host disease (Q27016541) (← links)
- NF-kappaB and the regulation of hematopoiesis (Q28301261) (← links)
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting (Q30486842) (← links)
- Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells (Q33262643) (← links)
- Proteasome inhibition suppresses essential immune functions of human CD4+ T cells (Q33316357) (← links)
- Proteasome inhibition reduces donor-specific antibody levels (Q33383491) (← links)
- A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity (Q33573863) (← links)
- Current and future approaches for control of graft-versus-host disease (Q33642625) (← links)
- Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms (Q33771667) (← links)
- Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice (Q33792598) (← links)
- Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. (Q33862527) (← links)
- Advances in graft-versus-host disease biology and therapy (Q34031916) (← links)
- Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors (Q34079116) (← links)
- Proteasome: target for acute and chronic GVHD? (Q34136973) (← links)
- Treatment of chronic graft-versus-host disease with bortezomib (Q34137032) (← links)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio (Q34202277) (← links)
- Proteasome inhibitor bortezomib ameliorates intestinal injury in mice (Q34222685) (← links)
- Proteasome inhibitors in the treatment of multiple myeloma (Q34611676) (← links)
- Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels (Q34624143) (← links)
- Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): Early role for STAT1 and STAT3 (Q34703720) (← links)
- Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation (Q35586614) (← links)
- A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease (Q35737769) (← links)
- Emerging therapies in hematopoietic stem cell transplantation (Q35825522) (← links)
- Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity (Q35848453) (← links)
- Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity (Q36014986) (← links)
- Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors (Q36038899) (← links)
- NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. (Q36110806) (← links)
- Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation (Q36130498) (← links)
- A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial (Q36157163) (← links)
- Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma (Q36194663) (← links)
- Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation (Q36212400) (← links)
- Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice (Q36217025) (← links)
- Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). (Q36251308) (← links)
- Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity (Q36378038) (← links)
- Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects (Q36380188) (← links)
- Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review (Q36408216) (← links)
- Cellular therapy following allogeneic stem-cell transplantation (Q36612643) (← links)
- Proteasome inhibitors: antitumor effects and beyond (Q36649676) (← links)
- Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation (Q36835147) (← links)
- Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation (Q36849339) (← links)
- Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination (Q36874310) (← links)
- Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity (Q36891101) (← links)
- Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantation (Q36891433) (← links)